Alliancebernstein L.P. lessened its stake in Becton Dickinson and Co (NYSE:BDX) by 0.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 413,492 shares of the medical instruments supplier’s stock after selling 3,005 shares during the period. Alliancebernstein L.P. owned 0.15% of Becton Dickinson and worth $107,921,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Acropolis Investment Management LLC bought a new position in Becton Dickinson and during the 3rd quarter worth about $101,000. Truvestments Capital LLC bought a new position in Becton Dickinson and during the 3rd quarter worth about $105,000. Almanack Investment Partners LLC. bought a new position in Becton Dickinson and during the 2nd quarter worth about $105,000. Bartlett & Co. LLC grew its holdings in Becton Dickinson and by 2,900.0% during the 2nd quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after acquiring an additional 435 shares in the last quarter. Finally, Bridgeworth LLC bought a new position in Becton Dickinson and during the 2nd quarter worth about $131,000. 86.25% of the stock is currently owned by institutional investors.

In other news, Director Timothy M. Ring sold 42,000 shares of the firm’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the sale, the director now directly owns 93,688 shares in the company, valued at approximately $22,210,614.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Vincent A. Forlenza sold 16,866 shares of the firm’s stock in a transaction dated Tuesday, November 13th. The shares were sold at an average price of $237.61, for a total transaction of $4,007,530.26. The disclosure for this sale can be found here. Insiders sold a total of 75,908 shares of company stock worth $18,085,616 over the last 90 days. Company insiders own 1.00% of the company’s stock.

Several research analysts have issued reports on the stock. Wells Fargo & Co increased their target price on shares of Becton Dickinson and from $275.00 to $290.00 and gave the stock an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Piper Jaffray Companies dropped their target price on shares of Becton Dickinson and to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, November 6th. Royal Bank of Canada reiterated a “hold” rating and set a $248.00 target price on shares of Becton Dickinson and in a report on Friday, August 3rd. Barclays assumed coverage on shares of Becton Dickinson and in a report on Monday, October 15th. They set an “equal weight” rating and a $278.00 target price on the stock. Finally, Citigroup increased their target price on shares of Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. Five research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $253.79.

NYSE:BDX opened at $242.04 on Thursday. Becton Dickinson and Co has a fifty-two week low of $209.91 and a fifty-two week high of $265.87. The stock has a market capitalization of $65.12 billion, a PE ratio of 21.98, a PEG ratio of 1.68 and a beta of 1.19. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.84%. The business had revenue of $4.40 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same period last year, the business earned $2.40 EPS. The company’s revenue was up 39.0% compared to the same quarter last year. As a group, equities research analysts forecast that Becton Dickinson and Co will post 12.1 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 31st. Stockholders of record on Monday, December 10th will be issued a $0.77 dividend. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date of this dividend is Friday, December 7th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.25%.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2018/11/22/becton-dickinson-and-co-bdx-position-reduced-by-alliancebernstein-l-p.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Article: Float

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.